Contact
searchSearch
HMP Global
Login

Myelofibrosis Excellence Forum

Myelofibrosis
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Lucía Pérez-Lamas, MD
Videos
Momelotinib Demonstrates Real-World Efficacy, Improved Anemia Symptoms Among Patients With Myelofibrosis
02/07/2025
Momelotinib for the treatment of myelofibrosis and anemia demonstrated improved real-world patient outcomes and a favorable safety profile, according to research presented at the 66th ASH Annual Meeting.
Momelotinib for the treatment of myelofibrosis and anemia demonstrated improved real-world patient outcomes and a favorable safety profile, according to research presented at the 66th ASH Annual Meeting.
Momelotinib for the treatment of...
02/07/2025
Oncology
John Mascarenhas, MD
Videos
Latest Updates in Navtemadlin Therapy for Patients With Myelofibrosis
01/29/2025
John Mascarenhas, MD
Navtemadlin therapy demonstrated efficacy and safety for patients with JAK inhibitor relapsed/refractory myelofibrosis, as well as improved biomarkers of disease burden, according to data presented by John Mascarenhas, MD.
Navtemadlin therapy demonstrated efficacy and safety for patients with JAK inhibitor relapsed/refractory myelofibrosis, as well as improved biomarkers of disease burden, according to data presented by John Mascarenhas, MD.
Navtemadlin therapy demonstrated...
01/29/2025
Oncology
Prithviraj Bose, MD
Videos
Zilurgisertib Alone or Combined With Ruxolitinib Well-Tolerated Among Patients With Myelofibrosis
07/25/2024
Prithviraj Bose, MD, shares results from an ongoing study that demonstrate that zilurgisertib as monotherapy or in combination with ruxolitinib had a favorable tolerance profile among patients with myelofibrosis.
Prithviraj Bose, MD, shares results from an ongoing study that demonstrate that zilurgisertib as monotherapy or in combination with ruxolitinib had a favorable tolerance profile among patients with myelofibrosis.
Prithviraj Bose, MD, shares...
07/25/2024
Oncology
John Mascarenhas, MD
Videos
Examining Real-World Outcomes Among Patients With Myelofibrosis Treated With Pacritinib
07/17/2024
John Mascarenhas, MD, shares results of a retrospective study on the real-world treatment outcomes among patients with myelofibrosis who were treated with pacritinib.
John Mascarenhas, MD, shares results of a retrospective study on the real-world treatment outcomes among patients with myelofibrosis who were treated with pacritinib.
John Mascarenhas, MD, shares...
07/17/2024
Oncology
Claire Harrison, MD, FRCP, Guy’s and St. Thomas’ NHS Foundation Trust
Q&As
Elritercept Well-Tolerated, Demonstrates Potential Efficacy for the Treatment of Patients With Myelofibrosis
07/11/2024
Claire Harrison, MD, FRCP, shares results of the ongoing phase 2 RESTORE trial in which elritercept was generally well-tolerated and demonstrated potential efficacy for treating patients with myelofibrosis.
Claire Harrison, MD, FRCP, shares results of the ongoing phase 2 RESTORE trial in which elritercept was generally well-tolerated and demonstrated potential efficacy for treating patients with myelofibrosis.
Claire Harrison, MD, FRCP,...
07/11/2024
Oncology
Aaron Gerds, MD
Videos
Novel Updates in Frontline Myelofibrosis Treatment Research
06/25/2024
Aaron Gerds, MD, discusses data from the MANIFEST-2 and TRANSFORM-1 trials exploring first-line treatment options for patients with myelofibrosis, as well as analyzes the establishment of optimal clinical trial end points.
Aaron Gerds, MD, discusses data from the MANIFEST-2 and TRANSFORM-1 trials exploring first-line treatment options for patients with myelofibrosis, as well as analyzes the establishment of optimal clinical trial end points.
Aaron Gerds, MD, discusses data...
06/25/2024
Oncology
Aaron Gerds, MD
Videos
Examining Luspatercept Efficacy for Anemia and Transfusion Burden Among Patients With Myelofibrosis
06/24/2024
Aaron Gerds, MD, presents insights into data from a study in which luspatercept improved anemia and transfusion burden for patients with myelofibrosis, and explains next steps for investigating luspatercept in further clinical trials.
Aaron Gerds, MD, presents insights into data from a study in which luspatercept improved anemia and transfusion burden for patients with myelofibrosis, and explains next steps for investigating luspatercept in further clinical trials.
Aaron Gerds, MD, presents...
06/24/2024
Oncology
Marina Kremyanskaya, MD, PhD, Icahn School of Medicine
Videos
Rusfertide Improves Hematocrit Control and Decreases Use of Phlebotomy Among Patients With PV
05/28/2024

Featuring Marina Kremyanskaya, MD, PhD

Featuring Marina Kremyanskaya, MD, Ph...
Marina Kremyanskaya, MD, PhD, shares study results from the REVIVE trial in which rusfertide demonstrated improved hematocrit control and decreased the use of phlebotomy among patients with polycythemia vera.
Marina Kremyanskaya, MD, PhD, shares study results from the REVIVE trial in which rusfertide demonstrated improved hematocrit control and decreased the use of phlebotomy among patients with polycythemia vera.
Marina Kremyanskaya, MD, PhD,...
05/28/2024
Oncology
Eytan M Stein, MD
Q&As
Preventing Transformation and Adverse Events Among Patients With Myelofibrosis
03/07/2024

Featuring Eytan M Stein, MD

Featuring Eytan M Stein, MD
Eytan M Stein, MD, shares expert insights on preventing transformation and reducing the symptom burden of adverse events among patients with myelofibrosis.
Eytan M Stein, MD, shares expert insights on preventing transformation and reducing the symptom burden of adverse events among patients with myelofibrosis.
Eytan M Stein, MD, shares expert...
03/07/2024
Oncology
Eytan M Stein, MD
Q&As
Evaluating Efficacy and Safety of Pelabresib Among Patients With MDS/MPN
03/07/2024

Featuring Eytan M Stein, MD

Featuring Eytan M Stein, MD
Eytan M Stein, MD, discusses findings from the MANIFEST trial which evaluated the efficacy and safety of pelabresib among patients with acute leukemia, high-risk myelodysplastic syndrome, or MDS/MPN.
Eytan M Stein, MD, discusses findings from the MANIFEST trial which evaluated the efficacy and safety of pelabresib among patients with acute leukemia, high-risk myelodysplastic syndrome, or MDS/MPN.
Eytan M Stein, MD, discusses...
03/07/2024
Oncology

Recent News

News
Modakafusp Alfa Demonstrates Antitumor Activity Among Patients With Relapsed/Refractory Multiple Myeloma
04/02/2025
Emily Estrada
At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.
At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.
At a tolerable and safe dose,...
04/02/2025
Oncology
News
Quadruplet Therapy Demonstrates Efficacy for Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma
04/02/2025
Emily Estrada
Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.
Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.
Quadruplet therapy with...
04/02/2025
Oncology
News
Co-Occurrence of High-Risk Cytogenetic Abnormalities as a Predictive Marker for Multiple Myeloma
04/02/2025
Emily Estrada
The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.
The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.
The presence of 2 or more...
04/02/2025
Oncology
News
Pembrolizumab Plus Bevacizumab Shows Promise Among Previously Untreated Patients With Melanoma Brain Metastases
04/01/2025
Stephanie Holland
According to results from a phase 2 study, pembrolizumab plus bevacizumab demonstrated promise among previously untreated patients with melanoma brain metastases.
According to results from a phase 2 study, pembrolizumab plus bevacizumab demonstrated promise among previously untreated patients with melanoma brain metastases.
According to results from a...
04/01/2025
Oncology
News
Outcomes Without Adjuvant Radioactive Iodine Among Pediatric Patients With Papillary Thyroid Cancer
04/01/2025
Allison Casey
According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.
According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.
According to a retrospective...
04/01/2025
Oncology
News
Lenvatinib Plus High-Dose Radioiodine Therapy Shows Promise for Patients With Metastatic Well-Differentiated Thyroid Cancer
04/01/2025
Allison Casey
A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.
A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.
A study found the addition of...
04/01/2025
Oncology
News
Zenocutuzumab Demonstrates Durable Activity in NRG1 Fusion–Positive Solid Tumors
03/31/2025
Janelle Bradley
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study...
03/31/2025
Oncology
FDA Approval
Durvalumab Approved for Muscle Invasive Bladder Cancer
03/31/2025
Allison Casey
The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.
The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.
The US FDA approved neoadjuvant...
03/31/2025
Oncology
FDA Approval
FDA Expands Approval of Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate Cancer
03/28/2025
Stephanie Holland
Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...
Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...
Based on results from the...
03/28/2025
Oncology
FDA Approval
FDA Approves Cabozantinib for Patients With Locally Advanced or Metastatic Well-Differentiated pNETs and epNETs
03/26/2025
Stephanie Holland
Based on results from the CABINET trial, the FDA has approved cabozantinib for patients 12 years of age and older with unresectable locally advanced or metastatic well-differentiated pNETs and epNETs who experienced disease progression after...
Based on results from the CABINET trial, the FDA has approved cabozantinib for patients 12 years of age and older with unresectable locally advanced or metastatic well-differentiated pNETs and epNETs who experienced disease progression after...
Based on results from the...
03/26/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use